Ferroptosis and interstitial cystitis: a systematic review of preclinical evidence and molecular mechanisms.
Bagrat Grigoryan, Victoria Kasyan, Michael Baboudjian et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review examined preclinical studies on ferroptosis in interstitial cystitis/bladder pain syndrome (IC/BPS), focusing on molecular mechanisms and biomarkers. Four studies were included, revealing that ferroptosis is linked to bladder injury, characterized by decreased GPX4 and SLC7A11 expression, elevated malondialdehyde, and increased lipid ROS. Ferroptosis inhibitors showed potential in mitigating bladder damage.
Key findings
- Ferroptosis was associated with bladder injury, indicated by decreased GPX4 and SLC7A11 expression.
- Elevated malondialdehyde (MDA) and increased lipid ROS were observed in the studies.
- Ferroptosis inhibitors like dexrazoxane and hydrogen sulfide donors reduced bladder damage.
- Key regulatory pathways involved included Wnt/β-catenin, NF-κB, and Nrf2.
Why it matters
Understanding the role of ferroptosis in IC/BPS could lead to novel therapeutic strategies targeting this pathway, potentially improving treatment options for a condition with limited current therapies.
What to keep in mind
The review included only four preclinical studies, and none evaluated pain-related outcomes or functional bladder parameters.